Managing urinary incontinence in women - a review of new and emerging pharmacotherapy.

Managing urinary incontinence in women - a review of new and emerging pharmacotherapy. Expert Opin Pharmacother. 2018 Oct 10;:1-9 Authors: Bientinesi R, Sacco E Abstract INTRODUCTION: The pharmacological treatment of urinary incontinence and overactive bladder (OAB) has been, for a longer time, based on antimuscarinic agents. In recent years, two other pharmacological principles have been introduced for the treatment of OAB and urgency urinary incontinence: the β3-adrenergic agent mirabegron and botulinum neurotoxin. Meanwhile, there is lack of effective drugs for the treatment of stress incontinence. Areas covered: This literature review presents synthetic compounds aimed to treat female urinary incontinence that are in phase II-III clinical development. Expert opinion: Antimuscarinic agents will continue to represent the current gold standard for the first-line pharmacological management of OAB and urgency urinary incontinence. The class of β3-agonists will certainly expand with the discovery and clinical development of novel agents. Combination therapy of antimuscarinic agents and β3-agonists could offer an alternative treatment in these patients, including those with symptoms refractory to first-line monotherapy. A huge number of preclinical studies are underway in this field exploring the therapeutic potential of many novel compounds while some have advanced to clinical phases of development. PMID: 30304645 [PubMed - ...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research